The article was written by Motek Moyen ResearchSeeking Alpha’s #1 Writer on Long Ideas and #2 in Technology – Senior Analyst at I Know First.
Summary:
Autodesk’s stock already has a year-to-date return of +24.04%. I still reiterate a buy rating for this 3D/CAD/CAM software leader.
I argued six months ago that ADSK can shoot up to $200. This price target could turn out to be true within the next six months.
My fearless forecast is that Autodesk will soon return to consistent profitability after most of its customers switch to the subscription-only model.
More than 95% of ADSK shares are owned by institutional investors. Small retail investors can profit from imitating the stock picking bets of institutional investors.
The 30-day technical indicators and moving averages points to ADSK as a buy. I Know First’s AI stock picking algorithm also has a very bullish one-year forecast for ADSK.
The article was written by Motek Moyen ResearchSeeking Alpha’s #1 Writer on Long Ideas and #2 in Technology – Senior Analyst at I Know First.
Summary:
The software-centric business of Microsoft makes it a safer long-term investment than Apple.
Unlike Apple, Microsoft has zero hardware exposure to China’s cold war with Trump. The smartphone business has reached peak status and is already on the decline.
While Apple is growing its Services business segment, Microsoft’s cloud-first Software-As-A-Service will always generate the bigger revenue/net income.
Like Apple and its iTunes iOS platform, Microsoft is also a giant beneficiary of the growing video games industry.
I Know First has a very bullish 12-month market trend forecast for MSFT.
Since the beginning of 2018 Arrowhead Pharmaceuticals showed growth catalysts for this year. First, according to the quarterly report for the period ended December 31, 2017, on September 28, 2016 the Company entered into a collaboration agreement with Amgen Inc. The Company received a worldwide license for ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target, that makes Amgen wholly responsible for clinical development and commercialization of this technology. Moreover, the Company has sold 3,002,793 common stocks to Amgen at a price of $7.16 each. This agreement seems to be still fruitful.
The Company entered into the license agreement with Janssen Pharmaceuticals, Inc. (part of the Janssen Pharmaceuticals Companies of Johnson & Johnson) for ARO-HBV and collaboration for up to three RNAi therapeutic candidates that use TRiM TM platform. The total deal value is approximately $3.7 billion. Additionally, on January 18, 2018 Arrowhead announced the pricing of an underwritten public offering of 10 million shares of its common stock at a price of $5.25 per share, before underwriting discounts. Net proceeds to the Company were approximately $56.7 million after deducting underwriting commissions and discounts and other offering expenses payable by the Company. This IPO gave undoubtedly a strong boost to the company’s finances. At the end of 2017, Arrowhead declared $11.5 million in cash, and $39.2 million in short-term investments.
I Know First’s Outlook
ARWR stock is one of the most predictable assets by I Know First’s AI algorithm and the above annual prediction provided an impressive result – the return totaled to 321.18%. Arrowhead stock was already mentioned in our previous winning stock forecast for different investment horizons, for instance our 3 months Winning stock forecast based on this bullish prediction by I Know First AI algorithm. In accordance with the our 1 year prediction for ARWR the stock price followed the below path:
Algorithmic traders utilize daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster.
To learn how you can become a subscriber today, click here.
Please note-for trading decisions use the most recent forecast.
The Company
Arrowhead Pharmaceuticals (NASDAQ: ARWR) develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company’s preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company’s pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-HBV is designed to silence the production of all hepatitis B virus (HBV) gene products. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency (AATD). ARO-AAT is designed to knock down the Alpha-1 antitrypsin (AAT) gene transcript and reduce the hepatic production of the mutant AAT protein.
The article was written by Motek Moyen ResearchSeeking Alpha’s #1 Writer on Long Ideas and #2 in Technology – Senior Analyst at I Know First.
Summary:
The stock price of 3D Systems has more than doubled since my last buy rating for it last February 23. I still endorse this stock as a buy.
My fearless forecast is that DDD can hit $30 within the next 12 months. Additive manufacturing’s gradual shift from prototyping to production applications is a long-term tailwind for 3D Systems.
The 2018 Wohlers Report revealed that the 3D printing industry grew 21% to $7.3 billion in 2017. Sales of 3D-printed parts from independent service bureaus contributed $2.995 billion.
I Know First’s AI still gives DDD a bullish one-year algorithmic market trend forecast.
I Know First-Daily Market Forecast, does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, stock forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.
